Besremi
Named-patient access overview. Besremi is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Besremi (ropeginterferon alfa-2b-njft) is a long-acting monopegylated interferon alfa-2b developed by PharmaEssentia. The US Food and Drug Administration approved Besremi in November 2021 for the treatment of adults with polycythemia vera, a chronic myeloproliferative neoplasm. The drug is administered as a subcutaneous injection every two weeks during titration, with maintenance dosing typically extended to every four weeks once a stable haematologic response is achieved. Treatment is initiated and monitored by a haematologist with myeloproliferative neoplasm expertise; structured mental-health screening (including depression and suicidality assessment) is required because interferon-class therapy carries neuropsychiatric warnings.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Besremi
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Besremi is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Besremi in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Besremi
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.